Bryn Mawr Trust Advisors LLC Acquires Shares of 46,332 Becton, Dickinson and Company $BDX

Bryn Mawr Trust Advisors LLC bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX) in the 2nd quarter, HoldingsChannel reports. The fund bought 46,332 shares of the medical instruments supplier’s stock, valued at approximately $7,011,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in BDX. Mill Capital Management LLC purchased a new stake in shares of Becton, Dickinson and Company in the second quarter worth approximately $522,000. Northstar Group Inc. purchased a new position in shares of Becton, Dickinson and Company during the second quarter valued at approximately $240,000. Northside Capital Management LLC boosted its position in shares of Becton, Dickinson and Company by 18.3% during the second quarter. Northside Capital Management LLC now owns 61,324 shares of the medical instruments supplier’s stock valued at $9,280,000 after buying an additional 9,494 shares during the last quarter. Cardinal Capital Management Inc. grew its holdings in Becton, Dickinson and Company by 6.6% during the second quarter. Cardinal Capital Management Inc. now owns 178,421 shares of the medical instruments supplier’s stock worth $27,000,000 after buying an additional 11,039 shares in the last quarter. Finally, Tema ETFs LLC raised its position in Becton, Dickinson and Company by 9.5% in the 2nd quarter. Tema ETFs LLC now owns 5,006 shares of the medical instruments supplier’s stock valued at $758,000 after buying an additional 435 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have weighed in on BDX. Evercore set a $180.00 price objective on Becton, Dickinson and Company in a research note on Monday, July 6th. Barclays increased their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a report on Monday, May 11th. The Goldman Sachs Group cut their price target on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a report on Wednesday, May 27th. UBS Group began coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, July 28th. They issued a “buy” rating and a $190.00 price objective for the company. Finally, TD Cowen lifted their target price on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company presently has a consensus rating of “Hold” and an average price target of $185.67.

Becton, Dickinson and Company Trading Up 0.7%

NYSE BDX opened at $183.16 on Friday. The business’s fifty day moving average is $157.84 and its 200-day moving average is $161.70. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51. The stock has a market capitalization of $50.47 billion, a price-to-earnings ratio of 55.17, a PEG ratio of 12.82 and a beta of 0.19. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last posted its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The business had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same quarter last year, the company posted $3.68 earnings per share. The firm’s quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Equities research analysts predict that Becton, Dickinson and Company will post 12.67 EPS for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be issued a dividend of $1.05 per share. This represents a $4.20 annualized dividend and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is 126.51%.

Insiders Place Their Bets

In other news, EVP Michael David Garrison sold 1,100 shares of the stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total transaction of $160,226.00. Following the completion of the transaction, the executive vice president owned 13,172 shares in the company, valued at approximately $1,918,633.52. This represents a 7.71% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the completion of the sale, the executive vice president directly owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 11,779 shares of company stock valued at $1,974,669 over the last ninety days. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.